Prognostic markers of immune-related adverse events in cancer therapy with checkpoint inhibitors: an uncontrolled, open-label, prospective cohort study
Medical academic journal · 26.12.2025 · 25 (4) · 93-106
DOI: 10.17816/maj637360 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Medical academic journal, online erschienen am 26.12.2025. Verfasst von V. V. Khizha und 7 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
BACKGROUND: Immune checkpoint inhibitors are highly effective in treating malignant neoplasms, but they often cause immune-related adverse events. The mechanisms of their pathogenesis are not well understood, and there are no reliable markers in clinical practice for assessing the risk of their occurrence. This study addresses the lack of research by validating a panel of markers. This will allow for personalized preventive management of patients and reduce the frequency of premature treatment discontinuation. AIM: The study aimed to identify the most informative prognostic markers for immune-related adverse events by evaluating dynamic changes in plasma cytokine levels in patients with malignant neoplasms who were receiving checkpoint inhibitor therapy. METHODS: A prospective study of patients with malignant neoplasms receiving checkpoint inhibitor therapy was conducted between 2023 and 2024 at the St. Petersburg Hospital of the Russian Academy of Sciences. The risk of immune-related adverse events was assessed as part of the dynamic observation (105 days with 2.0–2.5-week intervals). The primary endpoint was changes in plasma cytokine concentrations, determined by multiplex analysis and analyzed using nonparametric statistical tests such as the Shapiro–Wilk test, Mann–Whitney U test, and Šidák correction. RESULTS: The study included 21 patients with malignant neoplasms who completed the entire observation program. Six patients (28.6%) developed immune-related adverse events, whereas 15 (71.4%) did not. The development of immune-related adverse events was found to be associated with a significant increase in cytokine concentrations, suggesting a predominance of type 1 and type 17 T-helper cells. Of the evaluated biomarkers, interleukin 12p70 (IL-12p70), IL-15, and transforming growth factor-beta (TGF-β) had the greatest prognostic value for predicting complications. These biomarkers exhibited high sensitivity and specificity in pairwise group comparisons (p 0.005). During the manifestation of immune-related adverse events, the plasma concentrations of the following markers were as follows: IL 12p70: 2.51 [2.09–2.93] pg/mL; TGF-β: 14.54 [13.52–17.12] ng/mL; IL-15: 20.86 [15.51–26.21] pg/mL. The analysis confirmed that these markers are the most reliable predictors of an excessive immune response. No complications unrelated to the primary mechanism of action of the study therapy were reported. CONCLUSION: This study demonstrated for the first time the possibility of a predictive risk assessment for immune-related adverse events prior to checkpoint inhibitor therapy initiation based on IL-12p70, IL-15, and TGF-β levels. These findings allow for personalized patient management strategies that balance treatment efficacy with the prevention of complications. The study had two main limitations: its small sample size (n = 21) and the fact that patients were recruited from a single site.
Zitieren
APA
Khizha, V. V., Kozlova, D. I., Klyaus, N. A., Kuzin, S. O., Sholokhov, G. V., Khaimanova, D. G., Vasiliev, A. G., & Ballyuzek, M. F. (2025). Prognostic markers of immune-related adverse events in cancer therapy with checkpoint inhibitors: an uncontrolled, open-label, prospective cohort study. Medical academic journal, 25(4), 93-106. https://doi.org/10.17816/maj637360
Vancouver
Khizha VV, Kozlova DI, Klyaus NA, Kuzin SO, Sholokhov GV, Khaimanova DG, et al. Prognostic markers of immune-related adverse events in cancer therapy with checkpoint inhibitors: an uncontrolled, open-label, prospective cohort study. Medical academic journal. 2025;25(4):93-106. doi:10.17816/maj637360
BibTeX
@article{Khizha2025,
author = {Khizha, V. V. and Kozlova, D. I. and Klyaus, N. A. and Kuzin, S. O. and Sholokhov, G. V. and Khaimanova, D. G. and Vasiliev, A. G. and Ballyuzek, M. F.},
title = {Prognostic markers of immune-related adverse events in cancer therapy with checkpoint inhibitors: an uncontrolled, open-label, prospective cohort study},
journal = {Medical academic journal},
year = {2025},
volume = {25},
number = {4},
pages = {93--106},
doi = {10.17816/maj637360}
}
EUVIMED